云顶新耀-B(01952.HK):将获得候选产品SPR206在大中华等地域的相关专利权益
格隆汇 1 月 18日丨云顶新耀-B(01952.HK)公布,公司与Spero Therapeutics公司达成了一项授权合约的修订,根据该协定的修订内容,公司将获得候选产品SPR206在大中华区、韩国和部分东南亚国家("区域")的相关专利权益。2019年1月,两家公司曾宣布一项合作协定,在上述区域对SPR206进行开发、制造和商业化。SPR206是一款针对多重耐药("MDR")革兰氏阴性菌感染的创新治疗选择,目前仍在临床开发阶段。Spero公司此前发表了SPR2061期双盲、安慰剂对照的单次给药剂量递增(SAD)和多次给药剂量递增(MAD)临床试验资料,资料显示在针对目标多重耐药革兰氏阴性菌感染的治疗范围剂量内,SPR206耐受性良好。此外,在该研究中未观察到肾毒性的证据。Spero公司计划在2021年启动更多的1期研究,以评估SPR206进入肺间隔的渗透性和在肾功能不全患者中的药代动力学。
据悉,SPR206是一种潜在的同类领先的新型多黏菌素类抗生素,旨在减少目前临床上多黏菌素B和粘菌素治疗时产生的肾脏毒性。多黏菌素常被用作对抗多重耐药革兰氏阴性菌感染的最後手段,但它们在临床使用时与明显的神经毒性和肾毒性有关。公司的合作伙伴Spero Therapeutics公司在健康志愿者中进行的双盲、安慰剂对照1期临床试验中,在针对目标多重耐药革兰氏阴性细菌感染的可能治疗范围内,SPR206表现出良好的耐受性,更重要的是,在研究的剂量范围内也没有显示肾毒性的证据。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.